David Kaufman, who joined San Francisco-based Third Rock Ventures in 2020 and was promoted to partner at the company in 2022, has a varied resume outside of venture capital investing. He was previously chief medical officer and head of translational development at the Bill and Melinda Gates Medical Research Institute, and before that held several R&D roles at Merck & Co.
Founded in 2007, Third Rock invests in emerging fields of science and medicine. The group specializes in creating biotechs based on translational discoveries. “Our companies are based on bold ideas...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?